thiazoles has been researched along with Atypical Lipomatous Tumor in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alt, LAC; Chandar, N; Fay, MJ; Hayward, EA; Mathur, S; Noronha, S; Obrzut, J; Pillai, A; Rojas, J; Salamah, R; Scimeca, TE; Zanotti, B; Zarou, O | 1 |
| Andrisani, OM; Bi, P; Bidwell, CA; Castro, B; Durkes, A; Elzey, BD; Freeman, JL; Karki, A; Konieczny, SF; Kuang, S; Wang, C; Wirbisky, SE; Yue, F | 1 |
| Campbell, N; Chen, JH; Cory, DG; Dorfman, D; Enloe, BM; Fletcher, CD; Singer, S; Weybright, P | 1 |
| Benoist, F; Gauthier, A; McPherson, R; Vassiliou, G | 1 |
| Hsu, CL; Huang, SL; Yen, GC | 1 |
| Altiok, S; Brun, RP; Evans, RM; Fletcher, CD; Fletcher, JA; Forman, BM; Mueller, E; Oppenheim, H; Sarraf, P; Singer, S; Spiegelman, BM; Tontonoz, P | 1 |
| Campbell, N; Demetri, GD; Fletcher, CD; Mueller, E; Naujoks, R; Sarraf, P; Singer, S; Spiegelman, BM | 1 |
| Demetri, G; Goss, G | 1 |
1 review(s) available for thiazoles and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.
Topics: Chromans; Combined Modality Therapy; Disease Progression; Fatal Outcome; Humans; Liposarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retroperitoneal Neoplasms; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
1 trial(s) available for thiazoles and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.
Topics: Adult; Biopsy; Cell Differentiation; Chromans; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Ligands; Liposarcoma; Male; Middle Aged; Phosphatidylcholines; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Triglycerides; Troglitazone | 1999 |
6 other study(ies) available for thiazoles and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Topics: Adipocytes; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Cell Differentiation; Cell Line, Tumor; Cyclohexanecarboxylic Acids; Drug Screening Assays, Antitumor; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Liposarcoma; Mesenchymal Stem Cells; Phthalazines; Polyploidy; Protein Kinase Inhibitors; Thiazoles | 2018 |
Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice.
Topics: Adipocytes; Animals; Biomarkers, Tumor; Cell Dedifferentiation; Cell Differentiation; Cell Lineage; Cell Proliferation; Cell Transformation, Neoplastic; Diabetes Mellitus, Experimental; Diamines; Dibenzazepines; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lipid Metabolism; Liposarcoma; Metabolic Syndrome; Mice, Inbred C57BL; PPAR gamma; Precancerous Conditions; PTEN Phosphohydrolase; Receptors, Notch; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Xenograft Model Antitumor Assays | 2016 |
Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy.
Topics: 3T3 Cells; Adipocytes; Animals; Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Chromans; Flow Cytometry; Humans; Ligands; Liposarcoma; Magnetic Resonance Spectroscopy; Mice; Phosphatidylcholines; Phosphorylcholine; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma.
Topics: Adipocytes; Dimerization; Enhancer Elements, Genetic; Fibrinolytic Agents; Gene Expression; Humans; Ligands; Liposarcoma; Luciferases; Mutagenesis; Promoter Regions, Genetic; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Retinoic Acid; Response Elements; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2003 |
Growth inhibitory effect of quercetin on SW 872 human liposarcoma cells.
Topics: Annexin A5; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Humans; Intracellular Signaling Peptides and Proteins; L-Lactate Dehydrogenase; Liposarcoma; Membrane Potentials; Mitochondria; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Quercetin; Tetrazolium Salts; Thiazoles | 2006 |
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.
Topics: Adipocytes; Antigens, Differentiation; Cell Differentiation; Fibroblasts; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lipid Metabolism; Liposarcoma; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured | 1997 |